02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
19:10 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Mouse model herds

With the publication of its first set of data, the International Mouse Phenotyping Consortium (IMPC) has demonstrated it's making strides toward generating and characterizing the phenotypes of knockout models corresponding to the entire mouse genome...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin given on day 1 of each 3-week...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Amatuximab regulatory update

The European Commission granted Orphan Drug designation for Eisai's amatuximab to treat malignant pleural mesothelioma (MPM). The IgG1 antibody against glycoprotein-9 ( GP-9; CD42a) is in Phase II testing for MPM and...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Amatuximab: Interim Phase II data

Interim data from the open-label, international Phase II MORAb-009-003 trial in 89 chemotherapy-naïve patients with unresectable epithelial or biphasic pleural MM showed that 5 mg/kg amatuximab on days 1 and 8 of a 21-day cycle...
08:00 , Dec 21, 2009 |  BioCentury  |  Strategy

Eisai Inspired to Morph

With more than a decade gone by without a homegrown NME reaching the market, Eisai Co. Ltd. decided early in 2008 that it needed to make some drastic changes. Inspired by its recently acquired Morphotek...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

MORAb-009: Phase II started

Eisai's Morphotek Inc. subsidiary began a single-arm, open-label, international Phase II trial (MORAb-009-003) to evaluate IV MORAb-009 given on days 1 and 8 of a 21-day cycle for 6 cycles plus pemetrexed and cisplatin...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

MORAb-009 regulatory update

The EC granted Orphan Drug designation to Eisai's MORAb-009 to treat pancreatic cancer. The IgG1 antibody against glycoprotein-9 ( GP-9) is in Phase II testing in patients with inoperable pancreatic cancer. Eisai acquired MORAb-009...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

MORAb-009: Phase II started

Eisai's Morphotek Inc. subsidiary began a double-blind, international Phase II trial to evaluate gemcitabine plus MORAb-009 or placebo in up to 152 patients. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan   Product: MORAb-009   Business:...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Morphotek, Eisai deal

Eisai bolstered its oncology portfolio last September by acquiring the cancer product line of Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.) (see BioCentury, Sept. 11, 2006). Eisai also has E7389, a synthetic analog...